Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 5/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decitabine SCHEMBL10030513 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL9999636 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL661233 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL1651086 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL4006 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL117721 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL12800474 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20651628 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20769771 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL18402620 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235924-A2 | ANTI-CD123 IMMUNOCONJUGATES FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | IMMUNOGEN, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20230270771-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230270771-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230263818-A1 | COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230263818-A1 | COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| WO-2022093930-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-05-05 | — | — | WO | disclosed |
| EP-3962528-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD123 IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11224610-B2 | Low dose combination CDA substrate drug/cedazuridine with extended administration | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-01-18 | — | — | US | disclosed |
| WO-2020168241-A1 | X-REACTIVATION MODULATORS AND USES THEREOF | Flagship Pioneering Inc. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-20200085848-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-03-19 | — | — | US | disclosed |
| US-8268800-B2 | Certain compounds, compositions and methods | EISAI INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268800-B2 | Certain compounds, compositions and methods | EISAI INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2447272-A1 | 2'-Fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors | Eisai Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2207786-B1 | 2'-FLUORO-2'-DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | EISAI INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046457-A1 | PREPARATION OF DECITABINE | DR. REDDY'S LABORATORIES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2009052287-A1 | 2 ' -FLU0R0-2 ' -DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | EISAL CORPORATION OF NORTH AMERICA (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11224610-B2 | Low dose combination CDA substrate drug/cedazuridine with extended administration | CDA, DNMT1, DUT | DNMT1 2/4885ADRB1 4175/4885LMNA 2629/4885 |
| US-20230263818-A1 | COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS | DNMT3A, DNMT1, CDA | DNMT1 2/4885ADRB1 4478/4885LMNA 3551/4885 |
| US-20200085848-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | CDA, DNMT1, DUT | DNMT1 2/4885ADRB1 4175/4885LMNA 2629/4885 |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | DUT, TYMP, DPYD | DNMT1 111/4885ADRB1 4434/4885LMNA 1274/4885 |
| US-20230270771-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | CDA, DNMT1, DUT | DNMT1 2/4885ADRB1 4175/4885LMNA 2629/4885 |
| US-20120046457-A1 | PREPARATION OF DECITABINE | DNMT3A, DNMT1, DNMT3B | DNMT1 2/4885ADRB1 4149/4885LMNA 742/4885 |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | NTPCR, PNP, TYMP | DNMT1 898/4885ADRB1 3313/4885LMNA 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.